Beverly Teicher

21PUBLICATIONS
102CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEnglish languagePredictive and prognostic markersTō te Māori mātauranga hangarau, mātauranga atu anō, mātauranga haere tonu, me te mātauranga hapori (Māori technical, further, continuing and community education)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Apr 06, 2026
Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Edward Favours, Haiying Tang, Peyton Wong

|Mar 04, 2026
Improving Preclinical Cancer Drug Development Models to Avoid Clinical Failure.

David A Gewirtz, Beverly Teicher, Edward Greenberg

|Feb 19, 2026
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Beverly A Teicher, Li Chen, Dianne L Newton

|Feb 13, 2026
Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models.

Holly Lindsay, Yuchen Du, Lin Qi

|Oct 23, 2025
Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer.

Christopher W Schultz, Sourav Saha, Anjali Dhall

|Sep 17, 2025
RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Zahra Davoudi, Thomas S Dexheimer, Nathan P Coussens

Pageof 4

Frequent Collaborators

9 joint publications

Kenneth C Anderson

9 joint publications

Lewis C Cantley

9 joint publications

Riccardo Dalla-Favera

9 joint publications

Chi Van Dang